Skip to main content

Clinical Trial Search Results

A scientist pointing to an image of a DNA chain.

Clinical Trial Search Results

Showing 100-108 out of 310 results.

FABULINUS: A 52-week randomized, double-blind, placebo controlled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for preservation of pancreatic beta-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy.

Icon for trial | DRI17476 FABULINUS: A 52-week randomized, double-blind, placebo controlled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for preservation of pancreatic be

This study is currently enrolling.

Study Purpose: The study is aimed to evaluate an investigational drug, frexalimab, for preservation of pancreatic beta cell function in adults and adolescents that have been newly diagnosed with Type 1 Diabetes and started on i ...

NCT05901831

FINE-ONE: A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of Finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes

Icon for trial | 22267 FINE-ONE: A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of Finerenone versus placebo, in addition to standard of care, in participants with chronic ki

This study is currently enrolling.

Study Purpose: The aim of the study is to demonstrate efficacy of Finerenone when compared to placebo, in addition to standard of care, in delaying the progression of chronic kidney disease (CKD) in participants with CKD and T1 ...

NCT05364073

FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations

Icon for trial | FURMO-002 FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HE

This study is currently enrolling.

The purpose of this study is to learn about how the study drug, furmonertinib, works in patients with NSCLC who have a mutation in the EGFR or HER2 gene and how it may help them. For patients with this type of NSCLC, the study ...

NCT04628481

GLADIATOR: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline.

Icon for trial | LDX0319 GLADIATOR: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at base

This study is currently enrolling.

The purpose of this study is to check and collect data of how the body absorbs, distributes and gets rid of the study drug in the blood during the first cycle of LDX0319 study treatment. These data will help improve knowledge a ...